



Volume 1, Issue 5  
May 2022

# Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives E<sub>z</sub> - MINUTES

## Drugs Added to the VA National Formulary **WITHOUT** Prior Authorization (and associated posted documents)

- Filgrastim-sndz (ZARXIO injection syringes)-New National Contract to begin 6-30-2022
- Nicotine inhalation system (NICOTROL Inhaler) and Nicotine Nasal Spray (NICOTROL NS)
- Exemestane tablets (AROMASIN and multiple generics)
- ANTIHEMOPHILIC FACTOR, RECOMBINANT (standard half-life products)
- COAGULATION FACTOR IX, RECOMBINANT (standard half-life products)

## Drugs Added to the VA National Formulary **WITH** Prior Authorization (and associated posted documents)

- PCSK9 Inhibitors (Alirocumab-Preferred; Evolocumab-Non-preferred). The revised PCSK9 Inhibitor CFU direct providers to use PCSK9 inhibitors prior to inclisiran in appropriate high-risk candidates.
- Buprenorphine XR Inj SUBLOCADE

## Drugs Not Added to the VA National Formulary (and associated posted documents)

- Cyclosporine 0.1% Ophthalmic Emulsion (VERKAZIA)
- Estetrol/Drospirenone (NEXTSTELLIS)
- Extended half-life (EHL) factor VIII and IX products (Brand names: AFSTYLA, JIVI, ESPEROCT, ADYNOVATE, ELOCTATE and ALPROLIX, IDELVION, REBINYN)
- Ripretinib (QINLOCK)

## Formulary Drugs with Prior Authorization Removed (and associated posted documents)

- none

## Drugs Removed from the VA National Formulary (and associated posted documents)

- Tbo-filgrastim (GRANIX injection syringes)
- Mestranol/Norethindrone tablets (EQV-NORINYL 1+50)